ACLY and hepatocellular carcinoma: ACLY overexpression has been observed in lung cancer, pancreatic cancer, hepatocellular carcinoma, breast cancer, colorectal cancer, endometrial cancer, and glioblastoma, whereas tumor cells exhibited reduced metastatic activity by reducing low‐density lipoprotein cholesterol levels with phenylpropanoic acid, an ACLY inhibitor [89, 90, 91].